Biomind Labs Inc. announced the commencement of a commercial clinical trial on its proprietary drug candidate BMND06, a novel formulation based on the psychedelic molecule mescaline. Mescaline is a naturally occurring psychedelic compound which has received recognition of its possible therapeutic benefits for many decades. Mescaline acts similar to other psychedelic agents by binding to, and activating, the serotonin 5-HT2A receptor with high affinity.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.11 USD | -.--% | -.--% | +10.00% |
1st Jan change | Capi. | |
---|---|---|
+10.00% | 8.22M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- BMND.F Stock
- News Biomind Labs Inc.
- Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06